help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, F.
Right arrow Articles by Mucke, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, F.
Right arrow Articles by Mucke, L.
(American Journal of Pathology. 1999;155:1741-1747.)
© 1999 American Society for Investigative Pathology

Regular Articles

Elimination of the Class A Scavenger Receptor Does Not Affect Amyloid Plaque Formation or Neurodegeneration in Transgenic Mice Expressing Human Amyloid Protein Precursors

Frederick Huang*, Manuel Buttini*{dagger}, Tony Wyss-Coray*{dagger}, Lisa McConlogue{ddagger}, Tatsuhiko Kodama§, Robert E. Pitas*¶ and Lennart Mucke*{dagger}

From the Gladstone Institute of Neurological Disease*
and the Departments of Neurology{dagger}
and Pathology,
University of California, San Francisco, California; Elan Pharmaceuticals,{ddagger}
South San Francisco, California; and the Departments of Molecular Biology and Medicine,§
Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The class A scavenger receptor (SR) is expressed on reactive microglia surrounding cerebral amyloid plaques in Alzheimer’s disease (AD). Interactions between the SR and amyloid ß peptides (Aß) in microglial cultures elicit phagocytosis of Aß aggregates and release of neurotoxins. To assess the role of the SR in amyloid clearance and Aß-associated neurodegeneration in vivo, we used the platelet-derived growth factor promoter to express human amyloid protein precursors (hAPPs) in neurons of transgenic mice. With increasing age, hAPP mice develop AD-like amyloid plaques. We bred heterozygous hAPP (hAPP+/-) mice that were wild type for SR (SR+/+) with SR knockout (SR-/-) mice. Crosses among the resulting hAPP+/-SR+/- offspring yielded hAPP+/- and hAPP-/- littermates that were SR+/+ or SR-/-. These second-generation mice were analyzed at 6 and 12 months of age for extent of cerebral amyloid deposition and loss of synaptophysin-immunoreactive presynaptic terminals. hAPP-/-SR-/- mice showed no lack of SR expression, plaque formation, or synaptic degeneration, indicating that lack of SR expression does not result in significant accumulation of endogenous amyloidogenic or neurotoxic factors. In hAPP+/- mice, ablation of SR expression did not alter number, extent, distribution, or age-dependent accumulation of plaques; nor did it affect synaptic degeneration. Our results do not support a critical pathogenic role for microglial SR expression in neurodegenerative alterations associated with cerebral ß amyloidosis.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Because of the increasing age of many populations around the world and the lack of an effective cure, Alzheimer’s disease (AD) represents an increasing medical and socioeconomic problem.1,2 While the pathological hallmarks of the disease have been known for almost a century, the pathogenetic mechanisms by which amyloid plaques form and neurons are injured in AD remain poorly understood. Because amyloid plaque formation and Aß-associated degeneration of neuronal processes can be simulated in transgenic mice expressing mutant forms of the human amyloid protein precursor (hAPP),3-7 these models make it possible to test specific hypotheses regarding the etiology of these neuropathological alterations.

Recent pathological and cell culture studies have raised the possibility that the class A scavenger receptor (SR) may be causally involved in the pathogenesis of AD. The SR is a transmembrane protein expressed on mononuclear phagocytes that mediates the internalization and lysosomal degradation of a wide variety of molecules.8,9 Among the molecules that bind the SR are acetylated low-density lipoproteins (LDLs), oxidized LDLs, polyribonucleotides, dextran sulfate, and the Aß peptide, which appears to play a key role in AD pathogenesis.10-13 Histopathological analysis of AD brain tissue revealed prominent expression of the SR on reactive microglia surrounding amyloid plaques.14 In cell culture, the SR mediates the adhesion of microglia to surfaces coated with Aß fibrils and the microglial internalization of Aß microaggregates, raising the possibility that the SR is involved in the clearance of Aß from the brain.11,15 If the SR is indeed involved in Aß clearance in vivo, enhancement of its function might help diminish accumulation of amyloid plaques in patients with AD.

Further support for a potential role of the SR in neurodegeneration comes from studies showing that exposure to Aß leads to the activation of cultured microglia and to microglial release of neurotoxins, such as reactive oxygen species and neurotoxic amines.16,17 These effects may be mediated, at least in part, by interactions between Aß and the SR.11 If confirmed in vivo, such pathogenic Aß-SR interactions might constitute a useful therapeutic target in AD.

Here we show that the elimination of microglial SR expression does not affect amyloid deposition or neurodegeneration in hAPP transgenic mice. These findings suggest that the pharmacological manipulation of the SR may not be an effective strategy for preventing plaque formation or Aß-induced neurodegeneration in vivo.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Transgenic Mice

The generation of mice expressing hAPP from the platelet-derived growth (PDGF) factor B chain promoter has been described previously.3 The PDGF-hAPP line J97 selected for this study expresses an alternatively spliced minigene,18 hAPP, bearing the amyloidogenic V717F19 and K670M/N671L20 mutations that have been linked to familial AD (FAD). The line has been maintained by crossing heterozygous transgenic mice with nontransgenic (C57BL/6J x DBA/2) F1 breeders. The generation of SR-/- mice on a C57BL/6 x ICR hybrid background has also been described.21 Compared with SR+/+ mice, SR-/- mice have an increased susceptibility to infection by Listeria monocytogenes and herpes simplex virus type 1, but they show no obvious neurological or behavioral phenotype.21

Heterozygous hAPP transgenic mice (hAPP+/-) were crossed with homozygous SR knockout (SR-/-) mice, and the resulting offspring (hAPP+/-SR+/-) were intercrossed through brother-sister mating to obtain the genotypes used in this study. The resulting groups of littermates contained comparable random mixtures of the C57BL/6, DBA/2, and ICR strains. All mice used in this study were wild type for the mouse APP gene. Genomic DNA was extracted from tail biopsies and analyzed for the presence of the hAPP transgene and the endogenous SR gene, as outlined in Figure 1 .



View larger version (29K):
[in this window]
[in a new window]
  		Figure 1. Transgene constructs and polymerase chain reaction (PCR) analysis of genotypes. (a) PDGF-hAPP transgene and SR knockout strategy. The PDGF-hAPP transgene with which line J9 was generated contains the PDGF ß-chain promoter, an alternatively spliced hAPP minigene encoding the amyloidogenic V717F and K670M/N671L mutations, and SV40 sequences providing a polyadenylation signal.7,18 The SR knockout was achieved by inserting the neomycin resistance gene (Neo) into an EcoRI site disrupting exon 4.21 Elements are not drawn to scale. The locations of primers for analysis of genotypes by PCR are indicated. Primers: A (5'-GGCATGCGGATCGAGACATGATAAG-3') B (5'-GCTTTAAAAAACCTCCCACACCTCCCC-3') C (5'-AGAGAATCCAAAGCATTTCA-3') D (5'-TGAACATCAAGCAGTGTCAT-3') E (5'-GCTCAGAAGAACTCGTCAAG-3') F (5'-CGAATATCATGGTGGAAAAT-3') (b) PCR analysis of genotypes. Tail tissues were digested with proteinase K, and genomic DNA was amplified by a touch-down PCR protocol.48 Amplicons were separated electrophoretically on a 2% agarose gel and detected by staining with ethidium bromide. The PDGF-hAPP transgene was identified by amplifying the SV40 sequence at its 3' end. Amplification of DNA with GFAP primers (forward: 5'-GCGCGCTCGTGCACACTTATCACAC-3', reverse: 5'-CTGCCCCTGACTTCCTGGAAGCAC-3') was used to ensure the presence of DNA and efficiency of the Taq polymerase reaction in samples without an SV40 amplicon (not shown). SR-/- mice had a Neo amplicon but no SR amplicon, whereas the opposite was found in SR+/+ mice. SR+/- mice (not analyzed in this study) had amplification of Neo and SR sequences. No band was produced with primers C and D (see a) from the SR knockout allele because amplification of larger DNA fragments was relatively ineffective under the PCR conditions used.

 
Quantitation of Amyloid Plaques

Mice were euthanized by transcardial saline perfusion under anesthesia with chloral hydrate. Brains were removed rapidly, drop-fixed in phosphate-buffered 4% paraformaldehyde at 4°C for 72 h, and sectioned with a vibratome at 40 µm for neuropathological analysis. Plaques were quantitated by staining with thioflavin S or anti-Aß antibody. For thioflavin-S staining, vibratome sections were prepared from murine brain tissue as described,3,22 air-dried overnight on Superfrost slides (Fisher), fixed to the slides with 4% paraformaldehyde in 0.1 M phosphate buffer, and stained with a 1% thioflavin-S solution for 8 min. Sections were rapidly washed once in 100% ethanol and twice in 80% ethanol/water, rinsed for 10 min with water, and mounted with Vectashield fluorescent mounting medium (Vector). Sections were then analyzed by fluorescence light microscopy, using a fluorescein isothiocyanate (FITC) filter. For each mouse, thioflavin-S-positive plaques were counted in 10 sections (spaced 240 µm apart) from one hemibrain.

For Aß antibody staining, free-floating vibratome sections were stained with a monoclonal antibody against Aß (3D6; Elan Pharmaceuticals, South San Francisco, CA). Aß-bound primary antibody was visualized with a FITC-labeled secondary antibody. Sections were analyzed by laser scanning confocal microscopy with a Bio-Rad MRC-1024 mounted on a Nikon Optiphot-2 microscope. Digitized images were transferred to a Macintosh computer and analyzed with Image 1.5 (public domain program of W. Rasband) to determine the average percentage of the hippocampal area occupied by 3D6-positive amyloid deposits in three hippocampal sections per mouse. A similar approach has been used previously to quantitate amyloid plaque load in diseased human brains.23

Semiquantitative Assessment of Immunolabeled Presynaptic Terminals and Neuronal Dendrites

Immunolabeling of brain sections for synaptophysin (a marker of presynaptic terminals) and for microtubule-associated protein 2 (MAP-2) (a marker of neuronal cell bodies and dendrites), analysis of labeled sections with laser scanning confocal microscopy, and computer-aided semiquantitative analysis of confocal images were carried out essentially as described.22,24 Neuronal integrity was assessed in the outer molecular layer of the hippocampus. This brain region was chosen because it was previously found to exhibit neurodegenerative alterations in line J9 and other lines of FAD-mutant hAPP mice.3,7 Binding of primary antibodies (Boehringer Mannheim) was detected with an FITC-labeled secondary antibody (Vector). Sections were assigned code numbers to ensure objective assessment, and codes were not broken until the analysis was complete. For each mouse, we analyzed two brain sections per marker by laser scanning confocal microscopy and obtained four confocal images (two per section). Digitized images were transferred to a Macintosh computer and analyzed with Image 1.5. The density of MAP-2-immunoreactive dendrites or by synaptophysin-immunoreactive presynaptic terminals was determined and expressed as a percentage of the total image area as described.22,24

Statistical Analysis

All quantitative results are expressed as means ± SEM. Differences between means were assessed by Mann-Whitney U test. Differences among multiple means were evaluated by analysis of variance followed by Dunnett’s or Tukey-Kramer post hoc tests as appropriate. The null hypothesis was rejected at the 0.05 level. Analyses were made with Statview and SuperANOVA software (Abacus).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Elimination of the SR in hAPP Transgenic Mice

Mutations linked to FAD increase the production of the amyloidogenic Aß42 peptide (see refs. 13 and 25 for reviews), and transgenic mice expressing FAD-mutant hAPPs develop amyloid plaques and neurodegenerative changes resembling in several respects those found in humans with AD.3-6 To test in vivo whether the SR is critical to amyloid plaque formation and neurodegeneration, we crossed FAD-mutant hAPP mice that show high levels of human Aß expression7 with SR-/- mice,21 as described in Materials and Methods. The following genotypes were selected (Figure 1) for histopathological analysis: hAPP+/-SR+/+, hAPP+/-SR-/-, hAPP-/-SR+/+, and hAPP-/-SR-/-.

Lack of the SR Does Not Affect Amyloid Plaque Deposition in hAPP Mice

Amyloid deposition in hAPP+/-SR+/+ mice begins around 6–8 months of age.3,7,26 To assess whether lack of SR impairs Aß clearance and thereby accelerates amyloid deposition, we compared amyloid deposition in 6- and 12-month-old hAPP+/- mice that were wild type or knockout for the SR. Thioflavin S staining identified no plaques in hAPP-/- mice and revealed similar numbers and distributions of amyloid plaques in hAPP+/-SR+/+ and hAPP+/-SR-/- mice (Figures 2, 3a, 3b, and 4) , indicating that the absence of the SR did not accelerate or otherwise enhance amyloid deposition in hAPP+/- mice.



View larger version (108K):
[in this window]
[in a new window]
  		Figure 2. Similarity of amyloid plaques in hAPP mice that are wild type or knockout for the SR. Sagittal hippocampal sections from 12-month-old mice were stained either with thioflavin S (a, c, e, and g) or with an anti-Aß antibody (3D6) (b, d, f, and h) and imaged by confocal microscopy as described in Materials and Methods. hAPP-/- mice (a–d) had no amyloid plaques. The bright signal in the left lower portion of d represents a staining artifact. Comparable plaque deposition was found in SR+/+ and SR-/- mice expressing hAPP/Aß (e–h). Thioflavin S stains primarily ß-pleated sheets characteristic of more mature amyloid deposits, whereas 3D6 also labels more diffuse Aß deposits, which accounts for the difference in staining patterns obtained with these two markers. Scale bar, 180 µm.

 


View larger version (18K):
[in this window]
[in a new window]
  		Figure 3. Comparable age-dependent accumulation of amyloid plaques in hAPP mice that are wild type or knockout for the SR. Thioflavin S-positive plaques were visualized by fluorescence microscopy and counted at 6 (a) and 12 (b) months of age as described in Materials and Methods. Each data point represents results from a different mouse. No statistically significant effect of SR genotype was identified on plaque number in hAPP mice at 6 or 12 months of age. At 12 months, the average number of plaques per section was 8.8 ± 3.0 (mean) and 8.3 (median) in hAPP+/-SR-/- mice compared with 11.3 ± 4.5 (mean) and 6.6 (median) in hAPP+/-SR+/+ mice. c: The average area of hippocampus occupied by amyloid plaques at 12 months of age was assessed by staining three sections per animal with an anti-Aß antibody (3D6). The hippocampal areas occupied by Aß-positive deposits in hAPP+/-SR+/+ mice (mean, 2.2 ± 1.3%; median, 0.9%) and hAPP+/-SR-/- mice (mean, 1.6 ± 0.6%; median, 0.9%) were not significantly different.

 


View larger version (18K):
[in this window]
[in a new window]
  		Figure 4. Regional distribution of amyloid plaques in hAPP mice is unaffected by the SR. Thioflavin S-positive plaques were counted in different brain regions of 12-month-old mice (n = 8 per genotype) as described in Materials and Methods. Data represent the average number of plaques per section. The majority of plaques were found in the hippocampus, and there were no statistically significant differences in plaque numbers between hAPP+/-SR+/+ and hAPP+/-SR-/- mice for any of the brain regions analyzed.

 
Labeling of brain sections with the anti-Aß antibody 3D6 and measurements of the hippocampal area occupied by Aß-immunoreactive deposits confirmed the results of thioflavin-S staining: no significant difference was detected between hAPP+/- mice with or without SR expression (Figure 3c) . A substantial but comparable variability in plaque load was seen within the two groups of mice (Figure 3) , consistent with observations at early stages of plaque formation in other lines of hAPP+/-SR+/+ mice.5,7,27

The regional distribution and size of thioflavin S-stained plaques were also very similar in hAPP+/- mice with or without SR expression (Figures 2 and 4) . The plaque load was greatest in the hippocampus, and most callosal and neocortical plaques were found immediately overlying the hippocampus. No plaques were observed in the thalamus, cerebellum, or brainstem (data not shown).

Lack of the SR Does Not Affect Extent of Neurodegeneration in hAPP Mice

One of the best neuropathological correlates of cognitive deficits in AD is the loss of synaptophysin-immunoreactive presynaptic terminals in specific brain regions.28-31 Increased expression of Aß in PDGF-hAPP mice is also associated with a significant decrease in synaptophysin-immunoreactive presynaptic terminals in the outer molecular layer of the hippocampus and with more subtle decreases in MAP-2-immunoreactive neuronal dendrites.3,7 We therefore used confocal microscopy of immunolabeled brain sections and computer-aided image analysis to assess the integrity of presynaptic terminals and neuronal dendrites in the different groups of mice. This semiquantitative assessment of neurodegenerative alterations (see Materials and Methods for details) has been used successfully in diverse experimental models3,24,32 and in diseased human brains.22,33,34 It has also been validated previously by comparisons with quantitative immunoblots,35 quantitations of synaptic proteins by enzyme-linked immunosorbent assay,32,36 and modifications of the stereological "disector" approach.37

Compared with hAPP-/-SR+/+ controls, hAPP-/-SR-/- mice had normal levels of synaptophysin-immunoreactive presynaptic terminals (Figure 5) , suggesting that lack of the SR does not by itself result in abnormal central nervous system (CNS) development or neurodegenerative alterations.



View larger version (55K):
[in this window]
[in a new window]
  		Figure 5. Lack of SR expression does not prevent decrease in synaptophysin-immunoreactive presynaptic terminals in hippocampi of 12-month-old hAPP mice. a: Computer-aided image analysis was used to determine the density of synaptophysin-immunoreactive (SYN-IR) presynaptic terminals as described in Materials and Methods (seven or eight mice per genotype). SR-/- mice without hAPP/Aß expression had a normal density of immunolabeled presynaptic terminals compared with wild-type controls. In contrast, hAPP+/- mice showed significant decreases in immunolabeled presynaptic terminals (**P < 0.01 versus nontransgenic mice by Dunnett’s post hoc test (n.s.)). The difference between hAPP+/-SR+/+ and hAPP+/-SR-/- mice was not statistically significant. b: Sections from hAPP+/- mice with prominent decreases in SYN-IR presynaptic terminals are shown for illustration. Scale bar, 16 µm.

 
In contrast, hAPP+/- mice with or without SR expression had significant losses of synaptophysin-immunoreactive presynaptic terminals in the hippocampal outer molecular layer, but the presence or absence of the SR in these mice did not significantly affect the extent of neurodegeneration (Figure 5) . The density of MAP-2-immunoreactive neuronal dendrites in the outer molecular layer of the hippocampus was also reduced in hAPP+/- mice compared to hAPP-/- controls (P < 0.05 by Tukey-Kramer post hoc test), with similar levels observed in mice with or without SR expression (hAPP-/-SR+/+ 37.5 ± 1.3, hAPP-/-SR-/- 37.1 ± 1.3, hAPP+/-SR+/+ 31.8 ± 1.9, hAPP+/-SR-/- 32.3 ± 1.6; values represent percent of image area occupied).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Cell culture studies have implicated the SR in Aß clearance and Aß-induced neurotoxicity.11,15 Because both processes could play important roles in AD pathogenesis, pharmacological manipulation of the SR pathway might be considered for the development of better AD treatments. However, the present study demonstrates that ablation of the SR in transgenic mice expressing FAD-mutant forms of hAPP does not affect amyloid plaque formation or neurodegeneration in vivo.

Elimination of the SR did not significantly alter the type, extent, or distribution of amyloid plaques in the brains of hAPP transgenic mice at 6 or 12 months of age. These findings suggest that amyloid plaque formation, at least in these models, is not critically influenced by the SR. We cannot exclude the possibility that the high Aß levels in the brain of hAPP mice saturate SR-mediated Aß clearance processes, resulting in Aß deposition regardless of whether the SR has been eliminated or not. However, the genetic manipulation of other molecules such as apoE38 and transforming growth factor ß139 in a similar hAPP model can drastically alter amyloid deposition. Taken together, these studies indicate that the SR plays either no or only a minor role in plaque formation in these models.

To our knowledge, this is the first study to examine the cerebral cytoarchitecture of SR-/- mice. No differences between brains of SR-/- and SR+/+ mice at 6 or 12 months of age were detected by inspection of hematoxylin/eosin-stained sections (data not shown) or by the detailed confocal microscopic analysis described above. Thus the lack of the SR does not appear to affect CNS development or result in the significant accumulation of neurotoxic endogenous ligands. Although the measurements of amyloid deposition and of immunolabeled neuronal processes used in this study are sensitive, we cannot exclude the possibility that other aspects of CNS integrity or pathology might be affected by the absence of the SR.

Eliminating SR expression did not significantly alter the extent of neurodegenerative changes in hAPP mice. This suggests that microglial SR expression is not essential to the development of Aß-induced neurodegenerative alterations in vivo, at least not in these experimental models. It is possible that Aß injures neurons directly, rather than indirectly via microglial activation, an interpretation that is supported by the finding that fibrillar Aß is toxic to neurons in cell culture, even in the absence of microglia.40,41 Another potential explanation is that Aß induces neurotoxicity via alternative receptors.

Binding of Aß to the receptor for advanced glycation end products (RAGEs) activates cultured microglia and triggers them to release neurotoxins,42 and neuronal expression of the p75 neurotrophin receptor potentiates Aß-induced apoptosis in cultured neurons.43 The LDL receptor-related protein (LRP), like the SR, is a lipoprotein receptor with broad ligand specificity. It binds apolipoprotein E-enriched lipoproteins and functions as a receptor for the proteinase inhibitors Nexin II ({alpha}-secreted hAPP751) and {alpha}2-macroglobulin.9,44 {alpha}2-Macroglobulin avidly binds the Aß peptide45,46 and through interaction with LRP can mediate Aß uptake.47 The extent to which these and related pathways contribute to detrimental effects of Aß in AD or to the physiological clearance of Aß in vivo remains to be determined.


   Acknowledgements
 
We thank Mr. S. Ordway and Dr. G. Howard for editorial assistance, Mr. J. Carroll for help with graphics, Ms. G.-Q. Yu and Ms. H. Ordanza for expert technical assistance, Dr. E. Masliah for advice on the histological analysis of amyloid plaques and neurodegeneration, and Ms. D. Murray for help in the preparation of the manuscript.


   Footnotes
 
Address reprint requests to Dr. Lennart Mucke, Gladstone Institute of Neurological Disease, P.O. Box 419100, San Francisco, CA 94141-9100. E-mail: lmucke{at}gladstone.ucsf.edu

Supported in part by a grant from the U.S. Public Health Service (AG11385 to LM) and a Research Fellowship from the Howard Hughes Medical Institutes (to FH).

Accepted for publication July 7, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Hay J, Sano M, Whitehouse PJ: The costs and social burdens of Alzheimer disease: what can and should be done? Alzheimer Dis Assoc Disord 1997, 11:181-183
  2. Ernst RL, Hay JW: Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997, 11:135-145
  3. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J: Alzheimer-type neuropathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature 1995, 373:523-527[Medline]
  4. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F ß-amyloid precursor protein and Alzheimer’s disease. J Neurosci 1996, 16:5795-5811[Abstract/Free Full Text]
  5. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, Cole G: Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102[Abstract/Free Full Text]
  6. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997, 94:13287-13292[Abstract/Free Full Text]
  7. Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 1999, 96:3228-3233[Abstract/Free Full Text]
  8. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979, 76:333-337[Abstract/Free Full Text]
  9. Krieger M, Herz J: Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994, 63:601-637[Medline]
  10. Krieger M, Acton S, Ashkenas J, Pearson A, Penman M, Resnick D: Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J Biol Chem 1993, 268:4569-4572[Free Full Text]
  11. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: Scavenger receptor-mediated adhesion of microglia to ß-amyloid fibrils. Nature 1996, 382:716-719[Medline]
  12. Younkin SG: Evidence that Aß42 is the real culprit in Alzheimer’s disease. Ann Neurol 1995, 37:287-288[Medline]
  13. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM: Genetic association studies between dementia of the Alzheimer’s type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett 1997, 222:187-190[Medline]
  14. Christie RH, Freeman M, Hyman BT: Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer’s disease. Am J Pathol 1996, 148:399-403[Abstract]
  15. Paresce DM, Ghosh RN, Maxfield FR: Microglial cells internalize aggregates of the Alzheimer’s disease amyloid ß-protein via a scavenger receptor. Neuron 1996, 17:553-565[Medline]
  16. Meda L, Cassatella MA, Szendrei GI, Otvos LJ, Baron P, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by ß-amyloid protein and interferon-gamma. Nature 1995, 374:647-650[Medline]
  17. Giulian D, Haverkamp LJ, Li J, Karshin WL, Yu J, Tom D, Li X, Kirkpatrick JB: Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 1995, 27:119-137[Medline]
  18. Rockenstein EM, McConlogue L, Tan H, Gordon M, Power M, Masliah E, Mucke L: Levels and alternative splicing of amyloid ß protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer’s disease. J Biol Chem 1995, 270:28257-28267[Abstract/Free Full Text]
  19. Murrell J, Farlow M, Ghetti B, Benson MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 1991, 254:97-99[Abstract/Free Full Text]
  20. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of ß-amyloid. Nature Genet 1992, 1:345-347[Medline]
  21. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S, Kodama T: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-296[Medline]
  22. Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA: Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992, 32:321-329[Medline]
  23. Bartoo GT, Nochlin D, Chang D, Kim Y, Sumi SM: The mean Aß load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. J Neuropathol Exp Neurol 1997, 56:531-540[Medline]
  24. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994, 367:188-193[Medline]
  25. Selkoe DJ: Alzheimer’s disease: genotypes, phenotypes, and treatments. Science 1997, 275:630-631[Free Full Text]
  26. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and Aß42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997, 94:1550-1555[Abstract/Free Full Text]
  27. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M: Neuron loss in APP transgenic mice. Nature 1998, 395:755-756[Medline]
  28. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580[Medline]
  29. Zhan SS, Beyreuther K, Schmitt HP: Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia 1993, 4:66-74
  30. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P: Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995, 16:285-298;discussion 298–304[Medline]
  31. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ: Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997, 56:933-944[Medline]
  32. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW: Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci 1999, 19:4867-4880[Abstract/Free Full Text]
  33. Masliah E, Terry RD, Alford M, DeTeresa RM, Hansen LA: Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer’s disease. Am J Pathol 1991, 138:235-246[Abstract]
  34. Knowles RB, Gomez-Isla T, Hyman BT: Aß associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol 1998, 57:1122-1130[Medline]
  35. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR: Synaptotrophic effects of human amyloid ß protein precursor in the cortex of transgenic mice. Brain Res 1994, 666:151-167[Medline]
  36. Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, Welch E, Eagan KP, Hladik CL, White CLI: Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 1998, 57:955-960[Medline]
  37. Everall IP, DeTeresa R, Terry R, Masliah E: Comparison of two quantitative methods for the evaluation of neuronal number in the frontal cortex in Alzheimer disease. J Neuropathol Exp Neurol 1997, 56:1202-1206[Medline]
  38. Bales KR, Verina R, Dodel RC, Du R, Altstiel L, Bender B, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid ß-peptide deposition. Nature Genet 1997, 17:263-264[Medline]
  39. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L: Amyloidogenic role of cytokine TGF-ß1 in transgenic mice and Alzheimer’s disease. Nature 1997, 389:603-606[Medline]
  40. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW: Neurodegeneration induced by ß-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993, 13:1676-1687[Abstract]
  41. Lorenzo A, Yankner BA: ß-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994, 91:12243-12247[Abstract/Free Full Text]
  42. Yan SD, Chen X, Fu J, Chen M, Zhu HJ, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-ß peptide neurotoxicity in Alzheimer’s disease. Nature 1996, 382:685-691[Medline]
  43. Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE: Expression of the low-affinity nerve growth factor receptor enhances ß-amyloid peptide toxicity. Proc Natl Acad Sci USA 1994, 91:10703-10706[Abstract/Free Full Text]
  44. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK: LDL receptor-related protein, a multifunctional apoE receptor, binds secreted ß-amyloid precursor protein and mediates its degradation. Cell 1995, 82:331-340[Medline]
  45. Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM: {alpha}2-Macroglobulin as a ß-amyloid peptide-binding plasma protein. J Neurochem 1997, 69:299-305[Medline]
  46. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S: {alpha}2-Macroglobulin associates with ß-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 1998, 95:3275-3280[Abstract/Free Full Text]
  47. Narita M, Holtzman DM, Schwartz AL, Bu G: {alpha}2-Macroglobulin complexes with and mediates the endocytosis of ß-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 1997, 69:1904-1911[Medline]
  48. Hecker KH, Roux KH: High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. Biotechniques 1996, 20:478-485[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Shimizu, K. Kawahara, M. Kajizono, M. Sawada, and H. Nakayama
IL-4-Induced Selective Clearance of Oligomeric {beta}-Amyloid Peptide1-42 by Rat Primary Type 2 Microglia
J. Immunol., November 1, 2008; 181(9): 6503 - 6513.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
Y. Liu, S. Walter, M. Stagi, D. Cherny, M. Letiembre, W. Schulz-Schaeffer, H. Heine, B. Penke, H. Neumann, and K. Fassbender
LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide
Brain, August 1, 2005; 128(8): 1778 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Koenigsknecht and G. Landreth
Microglial Phagocytosis of Fibrillar {beta}-Amyloid through a {beta}1 Integrin-Dependent Mechanism
J. Neurosci., November 3, 2004; 24(44): 9838 - 9846.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
V. Laporte, Y. Lombard, R. Levy-Benezra, C. Tranchant, P. Poindron, and J.-M. Warter
Uptake of A{beta} 1-40- and A{beta} 1-42-coated yeast by microglial cells: a role for LRP
J. Leukoc. Biol., August 1, 2004; 76(2): 451 - 461.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. E. Bamberger, M. E. Harris, D. R. McDonald, J. Husemann, and G. E. Landreth
A Cell Surface Receptor Complex for Fibrillar beta -Amyloid Mediates Microglial Activation
J. Neurosci., April 1, 2003; 23(7): 2665 - 2674.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
E. Van Uden, M. Mallory, I. Veinbergs, M. Alford, E. Rockenstein, and E. Masliah
Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein
J. Neurosci., November 1, 2002; 22(21): 9298 - 9304.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
B. J. Bacskai, S. T. Kajdasz, M. E. McLellan, D. Games, P. Seubert, D. Schenk, and B. T. Hyman
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-beta In Vivo by Immunotherapy
J. Neurosci., September 15, 2002; 22(18): 7873 - 7878.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. S. Coraci, J. Husemann, J. W. Berman, C. Hulette, J. H. Dufour, G. K. Campanella, A. D. Luster, S. C. Silverstein, and J. B. El Khoury
CD36, a Class B Scavenger Receptor, Is Expressed on Microglia in Alzheimer's Disease Brains and Can Mediate Production of Reactive Oxygen Species in Response to {beta}-Amyloid Fibrils
Am. J. Pathol., January 1, 2002; 160(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. D. Webster, M. D. Galvan, E. Ferran, W. Garzon-Rodriguez, C. G. Glabe, and A. J. Tenner
Antibody-Mediated Phagocytosis of the Amyloid {{beta}}-Peptide in Microglia Is Differentially Modulated by C1q
J. Immunol., June 15, 2001; 166(12): 7496 - 7503.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. D. Bornemann, K.-H. Wiederhold, C. Pauli, F. Ermini, M. Stalder, L. Schnell, B. Sommer, M. Jucker, and M. Staufenbiel
A{beta}-Induced Inflammatory Processes in Microglia Cells of APP23 Transgenic Mice
Am. J. Pathol., January 1, 2001; 158(1): 63 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Mucke, G.-Q. Yu, L. McConlogue, E. M. Rockenstein, C. R. Abraham, and E. Masliah
Astroglial Expression of Human {{alpha}}1-Antichymotrypsin Enhances Alzheimer-like Pathology in Amyloid Protein Precursor Transgenic Mice
Am. J. Pathol., December 1, 2000; 157(6): 2003 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. D. Yan, A. Roher, A. M. Schmidt, and D. M. Stern
Cellular Cofactors for Amyloid {beta}-Peptide-Induced Cell Stress : Moving from Cell Culture to in Vivo
Am. J. Pathol., November 1, 1999; 155(5): 1403 - 1411.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. I. Brazil, H. Chung, and F. R. Maxfield
Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia
J. Biol. Chem., May 26, 2000; 275(22): 16941 - 16947.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Van Uden, Y. Sagara, J. Van Uden, R. Orlando, M. Mallory, E. Rockenstein, and E. Masliah
A Protective Role of the Low Density Lipoprotein Receptor-related Protein against Amyloid beta -Protein Toxicity
J. Biol. Chem., September 22, 2000; 275(39): 30525 - 30530.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Santiago-Garcia, J. Mas-Oliva, T. L. Innerarity, and R. E. Pitas
Secreted Forms of the Amyloid-beta Precursor Protein Are Ligands for the Class A Scavenger Receptor
J. Biol. Chem., August 10, 2001; 276(33): 30655 - 30661.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Le, W. Gong, H. L. Tiffany, A. Tumanov, S. Nedospasov, W. Shen, N. M. Dunlop, J.-L. Gao, P. M. Murphy, J. J. Oppenheim, et al.
Amyloid {beta}42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1
J. Neurosci., January 15, 2001; 21(2): RC123 - RC123.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, F.
Right arrow Articles by Mucke, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, F.
Right arrow Articles by Mucke, L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS